NDAORALTABLET
Approved
May 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FARESTON (toremifene citrate) is an oral selective estrogen receptor modulator (SERM) approved for breast cancer treatment. It functions as a non-steroidal antiestrogen, competing with estrogen for receptor binding in hormone-responsive breast tissue. The drug is indicated for metastatic breast cancer in postmenopausal women.
$0.088BPart D
LOE ApproachingDeclining
With LOE approaching and minimal Part D spending, this product faces significant revenue erosion; commercial team headcount is likely stable or contracting rather than expanding.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
Started Mar 2011
0Risk of Bone Fracture Occurrences
Career Relevance
FARESTON represents a mature, declining product with zero linked job openings, indicating minimal hiring and limited career advancement opportunities. Professionals assigned to this product will focus on defending share against generics, managing cost-of-goods-sold, and supporting existing patient relationships rather than pursuing strategic growth.
Brand Manager
Worked on FARESTON at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.